Perspective Therapeutics, Inc. (CATX)
NYSEAMERICAN: CATX · Real-Time Price · USD
3.480
+0.100 (2.96%)
Sep 12, 2025, 4:00 PM EDT - Market closed
Perspective Therapeutics Revenue
Perspective Therapeutics had revenue of $290.00K in the quarter ending June 30, 2025, a decrease of -44.87%. This brings the company's revenue in the last twelve months to $1.24M, down -15.64% year-over-year. In the year 2024, Perspective Therapeutics had annual revenue of $1.45M with 1.39% growth.
Revenue (ttm)
$1.24M
Revenue Growth
-15.64%
P/S Ratio
202.99
Revenue / Employee
$8,821
Employees
140
Market Cap
258.44M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.45M | 20.00K | 1.39% |
Dec 31, 2023 | 1.43M | -3.98M | -73.52% |
Dec 31, 2022 | 5.42M | - | - |
Jun 30, 2022 | - | - | - |
Jun 30, 2021 | 10.05M | 373.00K | 3.85% |
Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
CATX News
- 9 days ago - Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors - GlobeNewsWire
- 17 days ago - Perspective Therapeutics to Participate in Upcoming September Conferences - GlobeNewsWire
- 4 weeks ago - Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results - GlobeNewsWire
- 5 weeks ago - Perspective Therapeutics: Giving Us Some Valuable Perspective On Alpha Emitter Therapy - Seeking Alpha
- 7 weeks ago - Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025 - GlobeNewsWire
- 2 months ago - Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial - GlobeNewsWire
- 2 months ago - Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting - GlobeNewsWire